Identifying Shared Molecular Signatures Across Clinically Distinct Diseases

This direction is split into other directions: cross-disease transcriptomic integration. Its last version stays readable and citable here.

Version 1 of 137 papers41 conceptsfrozen 2026-10-04

Medicine has traditionally been organized by organ systems: cardiologists treat the heart, neurologists treat the brain, and oncologists treat tumors. However, at the molecular level, these clinical silos often break down. A growing body of research suggests that seemingly unrelated diseases—such as Alzheimer’s and osteoporosis, or COVID-19 and breast cancer—often share "molecular bridges" consisting of common gene expression patterns, regulatory networks, and signaling pathways.

By identifying these shared signatures, researchers can uncover the biological basis of comorbidities, discover "universal" biomarkers, and repurpose existing drugs to treat multiple conditions simultaneously.

The Transcriptomic Intersection

The most direct way to find shared mechanisms is to look for genes that are dysregulated in the same way across different conditions. This approach, often called cross-disease transcriptomic integration, involves taking gene expression data from two or more diseases and finding the "intersection" of their differentially expressed genes.

Sveinung Gundersen and colleagues pioneered this global view with the differential disease regulome, a map linking hundreds of transcription factors to over a thousand diseases. This bird's-eye view reveals that shared regulatory mechanisms are the rule rather than the exception. For instance, Melina Amor identified that MMP12 is consistently upregulated in both Type 2 Diabetes and cardiovascular disease, suggesting it as a high-impact target for patients suffering from both metabolic and heart conditions.

These intersections often reveal surprising links between peripheral infections and central degeneration. Ana Caroline Costa found a striking molecular overlap between the body’s response to herpes viruses and the signatures of Alzheimer’s, pointing to shared pathways in oxidative stress and immune signaling.

Hub Genes as Molecular Bridges

When two diseases share a significant number of genes, researchers look for "hub genes"—highly connected nodes in a biological network that act as the primary drivers of the shared pathology. These hubs function as molecular bridges between disparate clinical phenotypes.

For example, Wenzheng Zhang identified a bridge between Alzheimer’s and osteoporosis centered on the interaction between the inflammatory proteins PROK2 and CSF3. Similarly, Youfu Wang discovered that the ITK gene and monocyte infiltration drive both abdominal aortic aneurysms and rheumatoid arthritis.

Identifying these bridges is particularly useful for understanding why certain conditions frequently co-occur. Mingjian Kong demonstrated that PCOS and Type 2 Diabetes are linked by a shared network of cellular senescence genes, providing a biological explanation for their clinical comorbidity.

From Shared Genes to Shared Networks

While simple gene intersections are powerful, they can miss similarities where the genes are different but the pathways are the same. Silpa Suthram moved beyond individual genes to identify a universal signature of 59 functional protein modules that are dysregulated across half of all studied diseases. This suggests that many pathologies converge on a core set of biological failures.

Modern computational frameworks like NetColoc use network propagation to find these hidden overlaps. As described in Nature Protocols, this method can identify shared pathways between conditions like autism and heart disease even when they share almost no genes in common, by mapping them onto a global interaction network.

At the single-cell level, this "twinship" becomes even more apparent. S. Sebastian Pineda used single-cell RNA sequencing to show that ALS and FTLD share a common mechanistic failure in specific long-range projecting neurons, suggesting that therapeutic targets should focus on these pan-neuronal failure pathways rather than disease-specific symptoms.

Clinical Applications and Drug Repurposing

The ultimate goal of this research is to move from discovery to treatment. If two diseases share a molecular driver, a drug that works for one might work for the other.

  • Direct Repurposing: Mingyu Li showed that the antidepressant aprepitant could be repurposed to treat diabetic non-healing wounds because both conditions share the NK1R receptor pathway.
  • AI-Driven Discovery: Kexin Huang developed TxGNN, a foundation model that reasons over medical knowledge graphs to transfer therapeutic knowledge from well-studied common diseases to untreated rare diseases that share similar protein-interaction perturbations.
  • Universal Biomarkers: Yuek Ling Chai identified osteopontin as a bridge biomarker that tracks neuroinflammation in both Alzheimer’s and vascular cognitive impairment, allowing for a single test to monitor mixed-pathology conditions.

By shifting the focus from clinical labels to shared molecular signatures, this research direction is paving the way for a more unified, mechanism-based approach to medicine. As Kleanthi Lakiotaki argues, using a "statistical telescope" to scan biological data reveals that many "unrelated" diseases are actually molecular cousins, offering a vast and largely untapped map for drug repurposing and biological discovery.

Papers in this version

History & citationVersion 1 · 2026-10-04

Split into other directions · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_identifying_shared_molecular_signatures__cbd12fbf,
  title = {Identifying Shared Molecular Signatures Across Clinically Distinct Diseases},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/identifying-shared-molecular-signatures-across-clinically-distinct-diseases/rdr_cbd12fbfb0ee491ca5a810ee58d25fd0},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}

This exact version (version 1, frozen text):

@misc{lacuna_identifying_shared_molecular_signatures__cbd12fbf_v1,
  title = {Identifying Shared Molecular Signatures Across Clinically Distinct Diseases},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/identifying-shared-molecular-signatures-across-clinically-distinct-diseases/rdr_cbd12fbfb0ee491ca5a810ee58d25fd0/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}